Abstract
Objective To investigate the clinical efficacy of bevacizumab combined with chemotherapy in the treatment of recurrent ovarian cancer. Methods 36 patients pathologically confirmed with recurrent ovarian cancer were selected; and all received chemotherapy with pemetrexed+ lobaplatin; 3 weeks were 1 cycle; they were treated 4-6 cycles. Bevacizumab was intravenous infused 1 h before chemotherapy, 7.5 mg/kg for 2 cycles. The clinical efficacy, toxicity, and survival time were observed. Results 5 cases got CR, 13 PR, 10 SD, and 8 PD. The RR was 50.0%(18/36). The DCR was 77.8%(28/36). The main adverse reactions were gastrointestinal reaction, bone marrow suppression, and hypertension. The OS was (15.4±2.4) months. The PFS was (10.2±2.6) months. Conclusions Bevacizumab combining chemotherapy for recurrent ovarian cancer has relatively good clinical efficacy and can be a backup treatment scheme. Key words: Recurrent ovarian cancer; Chemotherapy; Bevacizumab; Survival time; Adverse reactions
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
